We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




RDW Levels Associated with Adverse Outcomes in COVID-19 Patients

By LabMedica International staff writers
Posted on 04 Feb 2021
Print article
Image: Human erythrocytes showing variation in red cell distribution width (RDW), known as anisocytosis, higher levels may predict mortality in COVID-19 patients (Photo courtesy of Dr. Graham Beards)
Image: Human erythrocytes showing variation in red cell distribution width (RDW), known as anisocytosis, higher levels may predict mortality in COVID-19 patients (Photo courtesy of Dr. Graham Beards)
The red cell distribution width (RDW) blood test measures the amount of red blood cell variation in volume and size. RDW is not used as an isolated parameter when interpreting a complete blood count (CBC); instead, it provides shades of meaning in the context of the hemoglobin (Hgb) and mean corpuscular value (MCV).

Increasing scientific evidence has shown that abnormalities in routine laboratory tests, particularly hematological tests, have the potential to indicate, in a quick, practical and economical way, the need for specific laboratory tests for the diagnosis of SARS-CoV-2 infection, besides assisting in the prognosis of the disease and in the optimization of its clinical monitoring.

Medical Scientists from several institutions including the Baim Institute for Clinical Research (Boston, MA, USA) performed a comprehensive literature search from inception to September 2020 to harvest original studies reporting RDW on admission and clinical outcomes among patients hospitalized with COVID-19. The study endpoint was adverse clinical outcomes, defined as the composite of mortality or severe COVID-19. A total of 14,866 patients from 10 studies were included in the meta-analysis. The mean age ranged from 38 to 77 years while the proportion of males ranged from 42.4% to 69.2%.

The investigators reported that the meta-analysis found that higher levels of RDW were associated with adverse outcomes in COVID-19 patients (mean differences, 0.72; 95% confidence interval [CI], 0.47-0.97; I2, 89.51%). Further, results of the subgroup analysis showed that deceased patients had higher levels of RDW compared to survived patients (mean differences, 0.93; 95% CI, 0.63-1.23; I2, 85.58%). Similarly, severely ill COVID-19 patients had higher levels of RDW, as opposed to patients classified to have milder symptoms (mean differences, 0.61; 95% CI, 0.28-0.94; I2, 82.18%).

Jane J Lee, PhD, the first author of the study, said, “Emerging evidence has underscored the potential usefulness of RDW measurement in predicting the mortality and disease severity of COVID-19. As RDW is widely available and included as a routine parameter of complete blood count, this simple laboratory test can be particularly useful in the context of COVID-19 pandemic, where identifying high-risk patients and facilitating timely intervention with limited resources are critical.”

The authors noted that the exact pathophysiology behind the association between increased RDW and adverse outcomes has yet to be elucidated. Numerous reports have suggested that COVID-19 infection was associated with an increase in the release and production of white blood cell counts and platelets from the bone marrow. The stimulation to the bone marrow may also impact the red blood cell (RBC) kinetics, resulting in a wider range of RBC size and subsequently elevated RDW levels. The study was published on January 15, 2021 in the Journal of Medical Virology.

Related Links:
Baim Institute for Clinical Research

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.